SCHEMBL12907471

SCHEMBL12907471

Cc1n[nH]c2cc(-c3ccc(C(=O)O)cc3)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.57
MAP2K4 P45985 6/20 0.56
MAPK1 P28482 4/20 0.56
MAPK6 Q16659 4/20 0.56
MAPKAPK3 Q16644 2/20 0.56
GRIK1 P39086 1/20 0.53
GRIK2 Q13002 1/20 0.53
GRIK3 Q13003 1/20 0.53
MAPKAPK5 Q8IW41 1/20 0.52
ABL1 P00519 2/20 0.50
BCR P11274 2/20 0.50
HDAC6 Q9UBN7 2/20 0.48
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
GSK3B P49841 2/20 0.47
FGFR1 P11362 2/20 0.46
FGFR2 P21802 2/20 0.46
FGFR3 P22607 2/20 0.46
JAK2 O60674 1/20 0.46
PDPK1 O15530 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31746650 0.87 DYRK1A (0.52) AAK1MAP2K4MAPK1MAPK6MAPKAPK3
SCHEMBL1144879 0.87 DYRK1A (0.52) AAK1MAP2K4MAPK1MAPK6MAPKAPK3
SCHEMBL12907256 0.83 JAK2 (0.69) AAK1MAP2K4MAPK1MAPK6MAPKAPK5
SCHEMBL12907457 0.82 JAK2 (0.67) MAP2K4GSK3BFGFR1FGFR2FGFR3
SCHEMBL13810906 0.81 AAK1 (0.67) AAK1MAP2K4MAPK1MAPK6HDAC6
SCHEMBL22926087 0.81 HPGD (0.51) ABL1BCRGSK3B
SCHEMBL12907451 0.81 FGFR1 (0.70) AAK1MAP2K4MAPK1MAPK6MAPKAPK3
SCHEMBL14397096 0.80 PDPK1 (0.53) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK5
SCHEMBL31504557 0.78 MAP2K4 (0.57) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK5
SCHEMBL1145076 0.78 MAP2K4 (0.57) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed